Inhibition of Na+/H+ exchanger activity by an alkyl-lysophospholipid analogue in a human breast cancer cell line. 1996

P Besson, and J Goré, and E Vincent, and C Hoinard, and P Bougnoux
Laboratoire de Physiologie et Biophysique Cellulaires, Faculté de Pharmacie, Université de Tours, France.

The mechanisms by which ET-18-OCH3 (1-O-octadecyl-2-O-methyl-sn-glycero-3 -phosphocholine) and other analogues of alkyl-lysophospholipids exert their antineoplastic effects are not yet fully elucidated. Possible interference with mechanisms involving intracellular pH (pHi) regulation was examined by measuring the effect of ET-18-OCH3 on the activity of the Na+/H+ exchanger in the breast cancer-derived cell line MCF-7. When ET-18-OCH3 was added to culture medium at 10 muM (determined as a noncytotoxic but cytostatic concentration), it led to an intracellular acidification (0.15 pH unit). It also decreased the rate of pHi recovery by Na+/H+ exchange following artificial acidification. Kinetic parameters of the exchange indicated that this was due to a decrease in the affinity of the exchanger for both transported ions, rather than to a decrease in the number of exchanger proteins in the membrane (same maximal efflux rate for treated and untreated cells). These results suggest that Na+/H+ exchanger inhibition and subsequent cytoplasmic acidification participate in the mode of action of ET-18-OCH3, and could be used for modulation of tumor-cell chemosensitivity or their subsequent commitment into programmed cell death.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D010742 Phospholipid Ethers Phospholipids which have an alcohol moiety in ethereal linkage with a saturated or unsaturated aliphatic alcohol. They are usually derivatives of phosphoglycerols or phosphatidates. The other two alcohol groups of the glycerol backbone are usually in ester linkage. These compounds are widely distributed in animal tissues. Ether Phosphatidates,Ether Phospholipids,Glycerol Phosphate Ethers,Glycerophosphate Ethers,1-Alkyl-2-Acylphosphatidates,1 Alkyl 2 Acylphosphatidates,Ethers, Glycerol Phosphate,Ethers, Glycerophosphate,Ethers, Phospholipid,Phosphate Ethers, Glycerol,Phosphatidates, Ether,Phospholipids, Ether
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002021 Buffers A chemical system that functions to control the levels of specific ions in solution. When the level of hydrogen ion in solution is controlled the system is called a pH buffer. Buffer
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D017923 Sodium-Hydrogen Exchangers A family of plasma membrane exchange glycoprotein antiporters that transport sodium ions and protons across lipid bilayers. They have critical functions in intracellular pH regulation, cell volume regulation, and cellular response to many different hormones and mitogens. Na(+)-H(+)-Antiporter,Na(+)-H(+)-Exchanger,Sodium-Hydrogen Antiporter,Na(+)-H(+)-Antiporters,Na(+)-H(+)-Exchangers,SLC9 Na(+)-H(+) Exchangers,SLC9 Protein Family,SLC9 Proteins,SLC9-NHE Protein Family,Sodium-Hydrogen Antiporters,Sodium-Hydrogen Exchanger,Sodium-Proton Antiporter,Sodium-Proton Antiporters,Solute Carrier 9 Protein Family,Solute Carrier 9 Proteins,Antiporter, Sodium-Hydrogen,Antiporter, Sodium-Proton,Antiporters, Sodium-Hydrogen,Antiporters, Sodium-Proton,Exchanger, Sodium-Hydrogen,Exchangers, Sodium-Hydrogen,Protein Family, SLC9,Protein Family, SLC9-NHE,SLC9 NHE Protein Family,Sodium Hydrogen Antiporter,Sodium Hydrogen Antiporters,Sodium Hydrogen Exchanger,Sodium Hydrogen Exchangers,Sodium Proton Antiporter,Sodium Proton Antiporters

Related Publications

P Besson, and J Goré, and E Vincent, and C Hoinard, and P Bougnoux
October 1986, The Journal of pharmacology and experimental therapeutics,
P Besson, and J Goré, and E Vincent, and C Hoinard, and P Bougnoux
November 1988, Cancer research,
P Besson, and J Goré, and E Vincent, and C Hoinard, and P Bougnoux
March 2012, Medical oncology (Northwood, London, England),
P Besson, and J Goré, and E Vincent, and C Hoinard, and P Bougnoux
March 1985, Biochemical and biophysical research communications,
P Besson, and J Goré, and E Vincent, and C Hoinard, and P Bougnoux
January 2009, Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology,
P Besson, and J Goré, and E Vincent, and C Hoinard, and P Bougnoux
November 2004, Oncogene,
P Besson, and J Goré, and E Vincent, and C Hoinard, and P Bougnoux
January 2006, Breast cancer research : BCR,
P Besson, and J Goré, and E Vincent, and C Hoinard, and P Bougnoux
November 1986, Cancer letters,
P Besson, and J Goré, and E Vincent, and C Hoinard, and P Bougnoux
January 1990, Journal of lipid mediators,
Copied contents to your clipboard!